ING: The impact of U.S. pharmaceutical tariffs is expected to be limited

```htmlGolden Ten Data reported on April 3 that ING economist Diederik Stadig stated in a report that the US’s imposition of a 100% tariff on pharmaceuticals may have limited impact on the industry. He expects the tariff to apply to branded drugs that have not yet reached exemption agreements, which will mainly affect economies such as Singapore and India. However, the scale of such product exports from these countries to the US is not significant. The tariff should be regarded as a signal of intensifying competition between the US and its rivals in the biotechnology and pharmaceutical industries.```